Adeno-associated viruses (AAV), a member of the Parvoviridae family, are small, single-stranded DNA viruses that infect humans and certain non-human primate species. To date, 13 serotypes and over 150 genotypes of AAV have been identified. AAV is widely regarded as non-pathogenic, with most infections triggering only a mild immune response.
AAV capsids serve as gene delivery vehicles, efficiently transferring genetic material into both dividing and quiescent cells. This unique capability makes AAV a preferred vector for gene therapy applications, as it allows for stable gene insertion into the host genome.
Different AAV serotypes exhibit tissue and cell-specific tropism, primarily due to variations in capsid structure and amino acid sequences. These differences enable AAV to interact with distinct host cell receptors, allowing targeted gene delivery. The ability to engineer recombinant AAV (rAAV) vectors has significantly advanced gene therapy, enabling the precise delivery of therapeutic genes to a wide range of tissues.
AAV-based gene therapy has been extensively studied, with multiple clinical trials utilizing different AAV serotypes for treating genetic disorders, neurodegenerative diseases, and other conditions. Some of the most widely used AAV serotypes in gene therapy include:
Monoclonal antibodies (mAbs) specific to AAV capsid proteins are essential tools for:
At ARP American Research Products, we offer a range of high-quality monoclonal antibodies designed for AAV serotype detection and characterization. These antibodies are optimized for applications such as ELISA, Western blot, immunofluorescence (IF), and flow cytometry.
Shop all AAV Products
